On 13 July 2015, the FDA approved gefitinib for the treatment of patients with advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R substitution mutations as detected by an FDA-approved test [84,85] (Table 1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.